Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

Home
/
update
/
details

GE HealthCare and University Medicine Essen Partner to Establish Theranostics Centre in Germany

NextEdge Admin

18 Oct 2024

2 min 32 sec

GE HealthCare has teamed up with University Medicine Essen (UME) to launch a new Theranostics Centre of Excellence in Germany, aimed at advancing precision care and expanding access to personalised cancer treatments.

The centre will integrate state-of-the-art technologies to support clinical practices and research both locally and globally. A key focus of the partnership is enhancing the production and availability of radioisotopes for precise disease diagnosis and monitoring. It will also offer advanced facilities for dose calculation, improved image quality, care coordination, and streamlined operations.

Dr. Ken Herrmann, Director and Chair of UME’s Clinic for Nuclear Medicine, highlighted the importance of theranostics in combining targeted therapies with precise diagnostic tools, enabling personalised treatment strategies. He emphasized the value of collaborating with industry leaders like GE HealthCare to drive innovation and improve patient outcomes through precision medicine.

Theranostics leverages diagnostic tracers and radioisotopes to obtain molecular-level insights unique to each patient's cancer cells. To support this effort, GE HealthCare will equip UME’s tracer development centre with radiopharmacy solutions, including cyclotrons, synthesisers, and lab technologies to facilitate the production of radioactive materials.

The centre will also deploy advanced molecular imaging systems, including the Omni Legend 32cm PET/CT, SIGNA PET/MR, and several SPECT/CT systems, enhanced with AI-powered tools such as Precision DL and Clarify DL.

In collaboration with GE HealthCare, UME researchers aim to expand the potential of PET/CT technology for cancer diagnosis, staging, treatment planning, and therapy monitoring. The partnership has already demonstrated success by validating AI models with 70–80% accuracy in predicting patient responses to immunotherapy.